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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S316All the patients are alive in remission at the present timewith
median post SCT survival of 9.4 months (2.1-18.5).
Conclusion: Posttransplant Rux appears to be safe and
feasible. Further investigation is warranted to elucidate
whether improved outcomes are due to a direct effect on the
primary marrow disorder, alleviation of the constitutional
symptoms or GvHD.Figure.457
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Background: Primary graft failure (pGF) after cord blood
transplantation (CBT) still occurs in roughly 10% of cases.
Although associated with a poor prognosis, cases diagnosed
early have an increased possibility of rescue with re-trans-
plantation. We considered an early stage diagnostic method
by elucidating mechanisms underlying post-CBT pGF.
Patients and Method: We analyzed 105 cases of single-unit
CBT at our institution. For pGF cases, we analyzed WBC dy-
namics (neutrophils, lymphocytes), chimerism, and fever,
and compared these parameters with delayed (>day 28) or
normal (day 28) engraftment cases.
Results: Of the evaluable 102 cases, 59 were normal engraft-
ment cases, 33 were delayed engraftment cases, and 10 were
pGF cases. Of the 10 pGF cases, 7 showed essentially no blood
cell count recoverybyday14, andsudden lymphocyte recovery
at amedian of day 18 (range,15-24) followedbygraft rejection.
Of the 4 assessed for chimerism at the time of lymphocyte in-
crease, all showed recipient-derived cells. 3 of the 10 pGF cases
never achievedWBC100/mL byday28. For engraftment cases,
lymphocyte number peaked at day 12, and almost cases
assessed for chimerism showed donor-derived cells. Only 1 of
the 67 cases which showedWBC>100/mL on day 12 indicated
pGF, whereas pGF was observed in 9 of the 33 cases in which
WBC was <100/mL (p<0.001). 72 cases had febrile episodes
which were associated with pre-engraftment immune reac-
tion. Theproportionof febrile (38C)casespeakedatday8 for
normal engraftment cases, day 11 for delayed engraftment
cases, and day 12.5 for pGF cases.
Conclusions: pGF likelihood should be considered for cases
of delayed timing of non-infectious fever, cases for which
WBC recovery is not seen at around day 12, and cases of
sudden lymphocyte recovery at around day 18.Table.
Age Sex Disease Prior
Auto
N prior
therapies
Status at
transplant
Donor CD34 dose 1
(x10e6/kg)
CD
(x
41 M FL Yes 4 CR MRD 3.18
87 M DLBCL Yes 3 PO MUD 1.9
64 M DLBCL No 2 PR MUD 1.84
54 F MCL No 2 PR MUD 10.19
52 M DLBCL Yes 4 PR MRD 2.94
69 M FL Yes 5 PR MUD 10.39
39 M DLBCL No 2 PR MUD 6.87
35 F DLBCL No 2 PR MRD 5.87
61 M DLBCL No 2 CR MMRD 7.9
46 F DLBCL No 1 CR MMUD 4.03 11458
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A subset of patients with advanced or relapsed B-cell lym-
phomas can be cured with allogeneic hematopoietic cell
transplantation (allo-HCT), but success is hampered by the
risk of recurrence and GVHD. Here we report the results of a
phase 2, single center trial combining anti-CD20 radio-
immunotherapy (RIT) with I-131 tositumomab and mTOR
inhibitionwith sirolimus for prevention of serious GVHD and
reduction in risk of relapse. Subjects (n¼10) received I-131
tositumomab 75cGi therapeutic dose on day -12, ﬂudarabine
25 mg/m2 IV on days -6 to -2 and melphalan 70 mg/m2 IV on
days -3 and -2 followed by peripheral blood grafts from 7/8
or 8/8 HLA matched related or unrelated donors. GVHD
prophylaxis consisted in sirolimus 12 mg PO loading dose on
day -14 in order to overlap with the conditioning regimen,
then 4mg PO daily with target blood level of 3-12 ng/ml, and3 dose
10e8/kg)
aGVHD
max
grade
cGVHD Time of
relapse
(months)
Follow-up
(months)
Outcome
3.38 3 Yes 8.9 18.4 Death from disease
0.3 0 Yes 63.6 Alive
2.97 0 Yes 60.8 Alive
3.57 0 Yes 10.2 Death from PE
4.22 0 Yes 9.3 33.0 Death from disease
1.61 0 Yes 13.6 25.1 Alive
2.24 0 No 17.1 18.0 Alive after relapse
3.01 0 No 4.5 14.0 Alive after relapse
3.01 0 Yes 9.8 Alive
2 0 Yes 8.9 Alive
